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Behaviour of protein carbonyl groups
in juvenile myocardial infarction
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Abstract. Acute myocardial infarction (AMI) is accompanied by oxidative stress, and protein oxidation is among the con-
sequences of oxidative stress. We examined the plasma concentration of protein carbonyl groups (PC), a marker of protein
oxidation, in a group of young subjects with AMI (45 men and 5 women; mean age 40.4 ± 4.8 yrs). We found a significant
increase of PC (p < 0.001) in comparison with normal controls. No difference was observed between patients with AMI char-
acterized by elevated ST segment and those without elevation of ST segment. There was no correlation between the ejection
fraction and PC in the whole group nor in the subgroups of STEMI and non-STEMI patients. Subdividing the whole group of
AMI patients according to the number of risk factors and the number of stenosed coronary vessels, the difference in PC level
was not statistically significant among the subgroups. This study showed an increased protein oxidation in young subjects with
recent AMI. Further investigation is needed to ascertain whether this can be a target of therapeutic intervention.
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1. Introduction
Acute myocardial infarction (AMI) is associated with increased synthesis of reactive oxygen/nitrogen
species (RONS) and the imbalance between RONS production and antioxidant systems (enzymatic and
non-enzymatic) leads to oxidative stress.
Up to now several are the reports concerning lipid peroxidation (LP) in AMI. An increase in LP
was found in AMI patients [12, 21, 26], with a progressive increase in the 7 days following the acute
event [21]. The LP increase was more evident in AMI complicated by cardiogenic shock [22]. LeLeiko
et al. [14] showed that F2-isoprostane, a marker of LP, predicted 30-day cardiovascular events in acute
coronary syndrome. Deepa et al. [6] found a LP increase in diabetic and non-diabetic AMI patients
compared to normal controls. Other authors [7] noted that in AMI patients with type 2 diabetes mellitus the
malonildialdheyde level was correlated with the glycometabolic parameters. Bagatini et al. [1] observed a
significant correlation between LP and troponin I in AMI patients. We have previously studied oxidative
stress in juvenile AMI, defined as AMI in patients aged <46 years, observing a decrease in total antioxidant
status and an increase in lipid peroxidation (LP), both still present 12 months after the acute event [17].
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Protein oxidation is among the effects of oxidative stress. When RONS attack aminoacids, protein
carbonyl groups (PC) are produced. They are constituted by oxidation of the side chains of lysine,
proline, arginine and threonine residues. Up to now the PC measurement is the most employed measure
of protein oxidation [5, 9].
Few are the data regarding the behaviour of protein oxidation in coronary heart diseases. A protein
oxidation increase, expressed as a high level of advanced oxidation protein products (AOPP), was found
in coronary artery disease and was related to the severity score of coronary lesions [13]. Serum protein
carbonyls were higher in patients with coronary artery disease and correlated with the obstructive vessel
number [23]. Some authors observed a protein oxidation increase in patients with AMI characterized
by elevated ST segment (STEMI) and not in those without elevation of ST segment (non-STEMI) [25].
This difference was not observed by others, who examined PC in 3 different groups of patients, with
respectively unstable angina, non-STEMI and STEMI [24]. In another report [8] the increase of protein
oxidation observed in STEMI patients was correlated with pain to hospital time and was associated with
higher incidence of adverse cardiac events. Bagatini et al. [1] observed, in comparison with healthy
controls, an increase of PC levels in AMI patients but also in a control group with cardiovascular risk
factors (smoking, hypertension, family history of heart disease). Other authors [2] observed an increase
of AOPP in a small group of AMI patients at the hospital admission, and a trend towards normal levels
after 1 and 6 months.
We previously described the behaviour of protein oxidation, expressed as PC levels, in patients with
mild essential hypertension [4] and in trained subjects [16]. The aim of the present study was to examine
protein oxidation, expressed as PC, in young subjects with recent AMI. This study is a part of the scientific
project identified as “Sicilian Study on Juvenile Myocardial Infarction”. In these patients we have recently
described the possible role of genetic polymorphisms as factors predisposing to AMI at young age [11].
2. Subjects and methods
In this research we examined 50 patients (45 men and 5 women) with recent AMI, aged <46 years. The
mean age was 40.4 ± 4.8 years. The time interval between AMI onset and the examination was 13 ± 7
days. In each patient we investigated the presence of the main cardiovascular risk factors, including
arterial hypertension, hypercholesterolemia, diabetes mellitus, family history of coronary artery disease
and current smoking habits. Arterial hypertension was defined as a systolic blood pressure >140 mmHg
and/or a diastolic blood pressure >90 mmHg and/or use of anti-hypertensive drugs. Diabetes was defined
as a fasting blood glucose level >125 mg/dl and/or use of hypoglycemic agents. Hypercholesterolemia
was defined as a total plasma cholesterol level >220 mg/dl and/or the use of lipid lowering drugs. Family
history consisted in any first-grade relative with clinical manifestations of coronary artery disease at age
<55 years. According to the number of risk factors the patients were subdivided into 3 groups: 14 of them
had 0 to 1 risk factor, 21 had 2 risk factors and 15 had 3 to 5 risk factors. Thirty-one patients had STEMI,
19 had non-STEMI. In each patient the ejection fraction (EF) was evaluated by echocardiography. The
mean EF in the whole group was 54.7 ± 6.6%; only 3 subjects had EF <45%. There was no significant
difference in EF between STEMI and non-STEMI patients. Coronary angiography was performed only
in 44 patients. In the other cases the patient refused his consent or the angiography was not performed
due to the long distance between the hospital in which AMI was diagnosed and the angiography unit. The
44 subjects in which coronary angiography was performed were subdivided into 3 groups on the basis
of the extent of coronary lesions: 9 patients did not show any significant coronary stenosis, 22 patients
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had a single-vessel disease (defined as a >70% stenosis in one coronary artery), and 13 patients had a
multi-vessel disease, that is a >70% stenosis in at least two coronary vessels. No patient had previous
manifestations of coronary artery disease or other comorbidities.
The control group included 42 subjects (35 men and 7 women; mean age 38.6 ± 5.3 yrs) without signs
of acute or chronic vascular diseases (history, physical examination, laboratory and instrumental tests).
The study was approved by the Ethical Committee and each subjects gave informed consent.
Blood samples were collected by venous puncture from the antecubital vein and immediately transferred
to glass tube anticoagulated with EDTA-K3; the parameter evaluated was protein oxidation.
2.1. Protein oxidation
PC were measured by an enzyme-linked immunosorbent assay (ELISA) kit (BioCell PC test kit, Enzo
Life Sciences AG, Switzerland). It uses the classic PC reagent 2,4-dinitrophenyl-hydrazine (DNP), which
reacts with the PC forming a stable hydrazone product.
In brief, plasma samples were incubated with DNP, and then plasma proteins were non-specifically
adsorbed to the wells of an ELISA plate. Unconjugated DNP and non-protein constituents were washed
away. The adsorbed proteins were probed with a biotinylated anti-DNP antibody, followed by streptavidin-
linked horseradish peroxidase. A chromatin reagent was added, and the reaction was stopped by adding
an acid solution. Absorbance for each well was measured at 450 nm and related to a standard curve
prepared for serum albumin, containing increasing proportions of hypochlorous acid-oxidized protein,
calibrated colorimetrically.
Total protein concentration in plasma samples was evaluated by the method of Lowry et al. [18].
3. Statistical analysis
Data were expressed as means ± SD; the difference between control subjects and young AMI patients
was evaluated according to the Student t test for unpaired data. The statistical difference between control
subjects and AMI patients subdivided according to the number of cardiovascular risk factors and to
the number of stenosed coronary vessels was evaluated according to the one-way analysis of variance
(ANOVA) model; then the Bonferroni multiple t test was performed to compare every pair of subgroups.
The correlation between EF and PC was evaluated by linear regression.
4. Results
In young AMI patients PC were significantly increased in comparison with control subjects
(C = 0.422 ± 0.129 nmol/mg prot; AMI patients = 0.605 ± 0.179 nmol/mg prot; p < 0.001). No signifi-
cant difference in PC was observed between STEMI (PC = 0.593 ± 0.189 nmol/mg prot) and non-STEMI
(PC = 0.594 ± 0.134 nmol/mg prot). Subdividing young AMI patients according to the number of
risk factors, no significant difference was observed between the three subgroups (Table 1); simi-
larly, subdividing AMI patients according to the number of stenosed coronary vessels, there was no
difference among the three subgroups (Table 1). There was no correlation between EF and PC in
the whole group nor in the subgroups of STEMI and non-STEMI patients. There was no signifi-
cant difference in PC when the main coronary stenosis regarded the left anterior descending artery
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Table 1
Means ± S.D. of protein carbonyl groups (PC) in control subjects and in AMI patients, subdivided according to the number of
risk factors (A) or to the number of stenosed coronary vessels (B)
A Control subjects AMI 0-1 risk
factors
AMI 2 risk
factors
AMI >2 risk
factors
F
PC (nmol/mg prot) 0.422 ± 0.129 0.581 ± 0.165# 0.593 ± 0.192∗ 0.645 ± 0.180∗ 10.61
B Control subjects AMI subjects
with no
coronary
lesions
AMI subjects
with 1
stenosed
vessel
AMI subjects
with 2 or 3
stenosed
vessels
F
PC (nmol/mg prot) 0.422 ± 0.129 0.659 ± 0.182∗ 0.597 ± 0.166∗ 0.575 ± 0.175§ 10.81
1p < 0.001 (ANOVA); p < 0.05 #p < 0.01 ∗p < 0.001 vs. control subjects (Bonferroni’s test).
(PC = 0.626 ± 0.182 nmol/mg prot), the left circumflex artery (PC = 0.501 ± 0.142 nmol/mg prot) or the
right coronary artery (PC = 0.604 ± 0.123 nmol/mg prot).
5. Conclusive considerations
Young AMI patients showed an increase in protein oxidation and this increase was present both in
STEMI and non-STEMI patients. The subdivision according to either the number of risk factors or the
extent of coronary disease showed an opposite trend: PC level was in fact higher in patients with more
risk factors and in those with less coronary lesions, although the differences between the AMI subgroups
did not reach statistical significance.
Our results confirm the literature data about the increase of protein oxidation found in AMI patients
not selected according to age [1, 2, 8, 24, 25], as well as our previous report concerning the behaviour
of lipid peroxidation in young AMI patients [17]. These data do not confirm the significant correlation
between protein oxidation and the severity of coronary disease which was observed by other authors [23].
There are some reports regarding short-term antioxidant treatments able to reduce lipid peroxidation
after AMI and reperfusion [3, 29]; moreover, antioxidants seem to have a cardioprotective action in
patients with chronic coronary artery disease [19]. As regards protein oxidation, there are data about the
carbonyl scavenger activity played by some molecules [10, 15, 20]; in particular L-arginine significantly
reduced the level of protein oxidation in ischemic heart disease [27, 28].
In conclusion, protein oxidation is a marker of the oxidative stress observed in young patients with recent
AMI. Oxidative stress is involved in atherogenesis, therefore its correction might reduce the progression
of the coronary atherosclerotic lesions and improve prognosis in these patients, but its effective usefulness
must be demonstrated by controlled long-term clinical studies.
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